Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
about
The Antibody Response against HIV-1Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesAnalysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infectionT cell virological synapses and HIV-1 pathogenesis.Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Characteristics of the earliest cross-neutralizing antibody response to HIV-1.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.Back to the future: covalent epitope-based HIV vaccine development.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategyTargeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.CD4 binding determinant mimicry for HIV vaccine design.Molecular determinants of the ratio of inert to infectious virus particles.N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationFactors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccineIdentification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation.Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.High mannose-specific lectin Msl mediates key interactions of the vaginal Lactobacillus plantarum isolate CMPG5300.Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotypeSimian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.Heterogeneity of envelope molecules shown by different sensitivities to anti-V3 neutralizing antibody and CXCR4 antagonist regulates the formation of multiple-site binding of HIV-1.Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.
P2860
Q27000889-A5EBF6E8-FE4D-4E54-807F-4FE9CB0988FAQ27318508-4A919EC3-884C-4A01-8EF8-E1CFD09EE273Q27472672-DD211AA2-BFED-440C-896A-D402DE1A3EE7Q28743199-DC8EC460-6EE8-467F-A430-419A802208E3Q28766705-A7F0F15E-ACBF-4D33-9E73-907C461E8237Q30415010-B32D605E-460B-4ACD-90BD-1F001BAD8FF4Q30447936-7F2253C9-4242-4D7E-908F-2F6BD7220DD8Q30480959-789CC6A3-BADD-4FE5-9D97-9646CFC779E7Q33374701-A9E3E1CD-CC8E-4493-B1AB-6C36824DA62DQ33725718-D3A2C89B-1638-4EE1-A96A-643D30C140A6Q33737656-186F24AD-EE38-4B69-B5CA-2AC98276F1B1Q33798076-C8C4AF83-0313-4BAC-B434-42427AA74E11Q33883887-CCD51F94-5931-497E-A688-714BFFBCC789Q34434753-61E89824-C6E4-4405-B1D9-2B024BE4220EQ34434854-4C0F478F-F3E1-4547-8A59-938FE91A6C4CQ34437201-2EB513EE-E4FF-4F50-9452-B391F1DFCEE1Q34597300-37613D9B-9EA1-42B0-9A20-938C302B4792Q35077716-2D797976-B254-449B-8477-C3381D1E95F9Q35785338-7D437DB3-88FB-4B28-8B0F-288B89262D50Q35826171-9248BDBD-E351-4223-983E-C485A4CE8703Q35849709-EAA76A06-0E62-4E5D-B8E4-74BFA92D003FQ36315745-23542620-7F42-443B-87ED-EB717D6F83F1Q36469664-76BDA0C4-6E14-4090-BEE5-FE852CCE9176Q36494676-5A6CA1C6-9AD6-4158-AA03-42210123CF04Q36565090-58D59947-B4D9-4610-901F-8833635155CFQ36736597-35583DC6-03AB-4C4A-AAB5-C55B85B6FD61Q36837815-FB378204-36C9-44F1-97A9-E9B0E91AB65BQ37033294-DC8A43FE-8F6F-4518-96EB-1FAC0393866EQ37123168-86E24E26-E415-42AA-8C52-D87D077118C9Q37127735-45C3B5C9-F01C-4E11-947B-9163CF5258E5Q37157165-D8E2433F-993D-41FC-B776-14DD23F782DFQ37410770-953ED3E2-23EF-468D-B9CF-5307ACFBD254Q37419063-7A6AF7FF-9745-4938-9093-D4FF078BC48BQ37419234-5CB3FEA2-6957-4141-ABB0-31F4400D8297Q37431843-694E66F6-A515-4F3D-85D2-2C139326B84EQ39305772-3B9467F2-2FB7-4F20-8816-275762424AB9Q39843176-06635DB7-BAF2-4B27-8E8E-55B2BF8407F7Q40311562-ACF268F7-A5B3-4DBA-AA2C-53F523A76468Q40563186-D7167D43-624A-4CD8-B704-4B90223A5205Q40909337-16BDD8E7-DCA0-4F9B-B567-F80B17AAD592
P2860
Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Nonneutralizing antibodies to ...... antibody against the same site
@en
Nonneutralizing antibodies to ...... ntibody against the same site.
@nl
type
label
Nonneutralizing antibodies to ...... antibody against the same site
@en
Nonneutralizing antibodies to ...... ntibody against the same site.
@nl
prefLabel
Nonneutralizing antibodies to ...... antibody against the same site
@en
Nonneutralizing antibodies to ...... ntibody against the same site.
@nl
P2093
P2860
P1433
P1476
Nonneutralizing antibodies to ...... antibody against the same site
@en
P2093
Carolina Herrera
Catherine Spenlehauer
Dennis R Burton
John P Moore
Michael S Fung
Simon Beddows
P2860
P304
P356
10.1128/JVI.77.2.1084-1091.2003
P407
P577
2003-01-01T00:00:00Z